Clostridium difficile Infections (CDI) - Opportunity Analysis and Forecasts to 2024 - PowerPoint PPT Presentation

Loading...

PPT – Clostridium difficile Infections (CDI) - Opportunity Analysis and Forecasts to 2024 PowerPoint presentation | free to download - id: 7ffa2f-ZWIyM



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Clostridium difficile Infections (CDI) - Opportunity Analysis and Forecasts to 2024

Description:

Research Beam added a report on “Clostridium difficile Infections (CDI) - Opportunity Analysis and Forecasts to 2024” Enquiry about report: – PowerPoint PPT presentation

Number of Views:13

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Clostridium difficile Infections (CDI) - Opportunity Analysis and Forecasts to 2024


1
OpportunityAnalyzer Clostridium difficile
Infections (CDI) - Opportunity Analysis and
Forecasts to 2024
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
TELEPHONE 1 (503) 894-6022E-MAIL
sales_at_researchbeam.com
Published on Oct 2014
2


Report Overview
  • Summary
  • Clostridium difficile, a Gram-positive,
    spore-forming, toxin-producing, non-invasive,
    anaerobic bacterium, is the causative organism of
    C. difficile infection (CDI), which is commonly
    associated with colitis, as well as C.
    difficile-associated diarrhea (CDAD). CDI onset
    begins with colonization of the intestinal tract
    with C. difficile through community-acquired or
    healthcare-associated means. C. difficile has
    been identified as a major cause of
    antibiotic-associated pseudomembranous colitis
    and diarrhea, with the earliest cases largely
    attributed to clindamycin. As penicillins and
    cephalosporins became more widely used throughout
    the years, their administration also became
    associated with an increased risk of developing
    CDAD. Since 2000, CDIs have become more frequent,
    more severe, more difficult to treat using
    existing therapies, and more likely to recur than
    previously described. These realities, along with
    increasing threat of antibiotic resistance,
    underscore the importance of developing
    CDI-specific therapies and bringing them to
    market.
  • Read More At http//www.researchbeam.com/opportun
    ityanalyzer-clostridium-difficile-infections-cdi-o
    pportunity-analysis-and-forecasts-to-2024-market

3


Table of Content
1 Table of Contents 121.1 List of Tables 181.2
List of Figures 21 2 Introduction 232.1
Catalyst 232.2 Related Reports 243 Disease
Overview 263.1 Etiology and Pathophysiology
263.2 Risk Factors and Symptoms 324
Epidemiology 454.1 Disease Background 454.2
Risk Factors and Comorbidities 465 Current
Treatment Options 835.1 Overview 835.2 Product
Profiles - Recommended Antibiotic Therapies 85
4


Table of Content
6 Unmet Needs Assessment and Opportunity Analysis
1166.1 Overview 1166.2 Improved Treatment
Options for Recurrent CDI 1197 Research and
Development Strategies 1407.1 Overview 1407.2
Current Approaches to CDI Product Development
1428 Pipeline Assessment 1608.1 Overview
1608.2 Promising Products in Clinical
Development 1619 Pipeline Valuation Analysis
2359.1 Clinical Benchmark of Key Pipeline
Products 2359.2 Commercial Benchmark of Key
Pipeline Products 23710 Appendix 26110.1
Bibliography 26110.2 Abbreviations 295 Enquire
At http//www.researchbeam.com/opportunityanalyz
er-clostridium-difficile-infections-cdi-opportunit
y-analysis-and-forecasts-to-2024-market/enquire-ab
out-report
5



FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/opportunityanalyzer-cl
ostridium-difficile-infections-cdi-opportunity-ana
lysis-and-forecasts-to-2024-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE 1 (800) 910-6452 DIRECT 1 (503)
894-6022E-MAIL sales_at_researchbeam.com
About PowerShow.com